Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.
dc.contributor.author | Hultcrantz, Malin | |
dc.contributor.author | Wilkes, Sally R | |
dc.contributor.author | Kristinsson, Sigurdur Y | |
dc.contributor.author | Andersson, Therese M-L | |
dc.contributor.author | Derolf, Åsa R | |
dc.contributor.author | Eloranta, Sandra | |
dc.contributor.author | Samuelsson, Jan | |
dc.contributor.author | Landgren, Ola | |
dc.contributor.author | Dickman, Paul W | |
dc.contributor.author | Lambert, Paul C | |
dc.contributor.author | Björkholm, Magnus | |
dc.date.accessioned | 2015-07-30T11:28:55Z | en |
dc.date.available | 2015-07-30T11:28:55Z | en |
dc.date.issued | 2015-07-10 | en |
dc.date.submitted | 2015 | en |
dc.identifier.citation | J. Clin. Oncol. 2015, 33 (20):2288-95 | en |
dc.identifier.issn | 1527-7755 | en |
dc.identifier.pmid | 26033810 | en |
dc.identifier.doi | 10.1200/JCO.2014.57.6652 | en |
dc.identifier.uri | http://hdl.handle.net/2336/561259 | en |
dc.description | To access publisher's full text version of this article click on the hyperlink at the bottom of the page | en |
dc.description.abstract | Myeloproliferative neoplasms (MPNs) are associated with a shortened life expectancy. We assessed causes of death in patients with MPN and matched controls using both relative risks and absolute probabilities in the presence of competing risks. | |
dc.description.abstract | From Swedish registries, we identified 9,285 patients with MPN and 35,769 matched controls. A flexible parametric model was used to estimate cause-specific hazard ratios (HRs) of death and cumulative incidence functions, each with 95% CIs. | |
dc.description.abstract | In patients with MPN, the HRs of death from hematologic malignancies and infections were 92.8 (95% CI, 70.0 to 123.1) and 2.7 (95% CI, 2.4 to 3.1), respectively. In patients age 70 to 79 years at diagnosis (the largest patient group), the HRs of death from cardiovascular and cerebrovascular disease were 1.5 (95% CI, 1.4 to 1.7) and 1.5 (95% CI, 1.3 to 1.8), respectively; all were statistically significantly elevated compared with those of controls. In the same age group, no difference was observed in the 10-year probability of death resulting from cardiovascular disease in patients with MPN versus controls (16.8% v 15.2%) or cerebrovascular disease (5.6% v 5.2%). In patients age 50 to 59 years at diagnosis, the 10-year probability of death resulting from cardiovascular and cerebrovascular disease was elevated, 4.2% versus 2.1% and 1.9% versus 0.4%, respectively. Survival in patients with MPN increased over time, mainly because of decreased probabilities of dying as a result of hematologic malignancies, infections, and, in young patients, cardiovascular disease. | |
dc.description.abstract | Patients with MPN had an overall higher mortality rate than that of matched controls, primarily because of hematologic malignancy, infections, and vascular events in younger patients. Evidently, there is still a need for effective disease-modifying agents to improve patient outcomes. | |
dc.language.iso | en | en |
dc.publisher | Grune & Stratton | en |
dc.relation.url | http://dx.doi.org/ 10.1200/JCO.2014.57.6652 | en |
dc.relation.url | http://jco.ascopubs.org/content/33/20/2288.full.pdf | en |
dc.rights | Archived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncology | en |
dc.subject | Krabbamein | en |
dc.subject | Dánartíðni | en |
dc.subject.mesh | Myeloproliferative Disorders | en |
dc.subject.mesh | Survival Rate/trends | en |
dc.subject.mesh | Population Surveillance | en |
dc.title | Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. | en |
dc.type | Article | en |
dc.contributor.department | Karolinska University Hospital, Karolinska Institutet, South Hospital, Stockholm, Sweden, University of Nottingham, Nottingham , University of Leicester, Leicester, United Kingdom, University of Iceland, Landspitali National University Hospital, Reykjavik, Iceland, Memorial Sloan Kettering Cancer Center, New York, NY., South Hospital, Stockholm, Sweden, | en |
dc.identifier.journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | en |
dc.rights.access | Landspitali Access - LSH-aðgangur | en |
html.description.abstract | Myeloproliferative neoplasms (MPNs) are associated with a shortened life expectancy. We assessed causes of death in patients with MPN and matched controls using both relative risks and absolute probabilities in the presence of competing risks. | |
html.description.abstract | From Swedish registries, we identified 9,285 patients with MPN and 35,769 matched controls. A flexible parametric model was used to estimate cause-specific hazard ratios (HRs) of death and cumulative incidence functions, each with 95% CIs. | |
html.description.abstract | In patients with MPN, the HRs of death from hematologic malignancies and infections were 92.8 (95% CI, 70.0 to 123.1) and 2.7 (95% CI, 2.4 to 3.1), respectively. In patients age 70 to 79 years at diagnosis (the largest patient group), the HRs of death from cardiovascular and cerebrovascular disease were 1.5 (95% CI, 1.4 to 1.7) and 1.5 (95% CI, 1.3 to 1.8), respectively; all were statistically significantly elevated compared with those of controls. In the same age group, no difference was observed in the 10-year probability of death resulting from cardiovascular disease in patients with MPN versus controls (16.8% v 15.2%) or cerebrovascular disease (5.6% v 5.2%). In patients age 50 to 59 years at diagnosis, the 10-year probability of death resulting from cardiovascular and cerebrovascular disease was elevated, 4.2% versus 2.1% and 1.9% versus 0.4%, respectively. Survival in patients with MPN increased over time, mainly because of decreased probabilities of dying as a result of hematologic malignancies, infections, and, in young patients, cardiovascular disease. | |
html.description.abstract | Patients with MPN had an overall higher mortality rate than that of matched controls, primarily because of hematologic malignancy, infections, and vascular events in younger patients. Evidently, there is still a need for effective disease-modifying agents to improve patient outcomes. |